Drilldown: Medicines
Medicines > onset 
:
Mood: 2–4 weeks. Pain: often within 1–2 weeks. or
Over weeks or
Postprandial glucose effect within days; HbA1c by 12 weeks
:
Mood: 2–4 weeks. Pain: often within 1–2 weeks. or
Over weeks or
Postprandial glucose effect within days; HbA1c by 12 weeks Use the filters below to narrow your results.
generic:
brand:
classes:
mechanism:
None (1) ·
Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) ·
Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
'"`UNIQ--vote-00000762-QINU`"' Largely renally cleared, hence the eGFR-tiered dosing. Rare but well-documented signals: acute pancreatitis (uncertain causal contribution), severe joint pain, and bullous pemphigoid (class effect, especially in older Asian patients)'"`UNIQ--ref-00000763-QINU`"'. (1)
uses:
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
Preventive treatment of migraine in adults (episodic and chronic) (1) ·
Preventive treatment of migraine in adults; episodic cluster headache (1) ·
'"`UNIQ--vote-00000764-QINU`"' (1) ·
'"`UNIQ--vote-0000117B-QINU`"' (1)
starting dose:
None (1) ·
100 mg PO once daily (50 mg if CrCl 30-44; 25 mg if <30 or dialysis) (1) ·
225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) ·
5 mg PO once daily (no renal dose adjustment, unlike sitagliptin) (1) ·
Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1)
preparations:
fda max:
routes:
onset: (Click arrow to add another value)
duration:
halflife:
bioavailability:
pregnancy:
Showing below up to 5 results in range #1 to #5.